Today the House Foreign Operations Subcommittee, one of two subcommittees that will decide FY 2006 funding allocations for the Millennium Challenge Account, held a hearing on the MCA. The sole witness was MCC CEO Paul Applegarth.
CGD Policy Blogs
Julian Lob-Levyt, executive secretary of the Global Alliance for Vaccines and Immunization and CEO of the Vaccine Fund, and Ciro de Quadros, director of international programs at the Sabin Vaccine Institute, write in the Philadelphia Inquirer (free registration) on the 50th anniversary of the polio vaccine.
Merck has filed for approval for Rotateq, its vaccine to protect against rotavirus gastroenteritis. Merck also announced that it has plans to file for licensure of Rotateq in Australia, Canada, the EU and Mexico, as well as countries in Asia and Latin America in 2005.
Maurice Hilleman died yesterday. Dr Hilleman was a researcher at Merck & Co until 1984, played a key role in the development of many vaccines, including mumps, measles, chickenpox, pneumonia, meningitis and other diseases, saving tens of millions of lives.
On April 12th, 1955, at a convocation at the University of Michigan, it was announced that the polio virus vaccine developed by Jonas Salk at the University of Pittsburgh was safe, effective and potent. Headlines around the world proclaimed "The Vaccine Works". The nickels and dimes that millions of Americans had donated to the March of Dimes had succeeded.
There is an interesting discussion unfolding on whether tiered prices for pharmaceuticals constitute a subsidy by Americans.
Here are some moments from this morning's launch of Making Markets for Vaccines that touched me personally.
GlaxoSmithKline today issued a press release welcoming the CGD Report, Making Markets for Vaccines.
Jean Pierre Garnier, CEO of GlaxoSmithKline, said;